Future Science Group
Browse
1/1
3 files

EFFECT OF PHARMACOGENOMIC TESTING ON PEDIATRIC MENTAL HEALTH OUTCOME; A 6 MONTH FOLLOW UP - supplemental material

figure
posted on 2022-12-05, 09:40 authored by Ahmed Z Elmaadawi, Rikin Patel, Yarob Almaaitah, Matthew G Logsdon

  

Supplementary Figure 1: Multiple regression of enzyme metabolizer status as reported from PGT on treatment outcomes. Of the enzymes tested, only COMT metabolizer status was significantly associated with better treatment outcomes.

  

Supplemental Figure 2: Trend of decreasing CGI Severity scores with COMT Val158 isoforms. The x-axis represents isoform types from PGT: 1 = homozygous COMT Met158/Met158; 2 = heterozygous COMT Met158/Val158; 3 = homozygous COMT Val158/Val158. Because Met158 variants have been shown to have lower activity than Val158 variants, these genotypes can be used as a rough proxy for metabolizer speeds, with Met158/Met158 and Val158/Val158 representing slow and fast metabolizers respectively.

  

Supplemental Figure 3: Mean values of CGI-improvement scores among individuals with ADHD tested for COMT variants are shown. Patients in each group experienced significant (p>0.001) improvement over baseline. While small sample sizes prevented conclusions of statistical significance, absolute improvement and odds of improvement were greatest for patients with Val/Val variants. 

History